13 June 2016 in Neurophotonics
Diffuse correlation spectroscopy (DCS) measurements of blood flow rely on the sensitivity of the temporal autocorrelation function of diffusively scattered light to red blood cell (RBC) mean square displacement (MSD). For RBCs flowing with convective velocity , the autocorrelation is expected to decay exponentially with , where is the delay time. RBCs also experience shear-induced diffusion with a diffusion coefficient and an MSD of . Surprisingly, experimental data primarily reflect diffusive behavior. To provide quantitative estimates of the relative contributions of convective and diffusive movements, we performed Monte Carlo simulations of light scattering through tissue of varying vessel densities. We assumed laminar vessel flow profiles and accounted for shear-induced diffusion effects. In agreement with experimental data, we found that diffusive motion dominates the correlation decay for typical DCS measurement parameters. Furthermore, our model offers a quantitative relationship between the RBC diffusion coefficient and absolute tissue blood flow. We thus offer, for the first time, theoretical support for the empirically accepted ability of the DCS blood flow index () to quantify tissue perfusion. We find to be linearly proportional to blood flow, but with a proportionality modulated by the hemoglobin concentration and the average blood vessel diameter.
13 November 2018 in Neurophotonics
Monitoring of cerebral blood flow (CBF) and autoregulation are essential components of neurocritical care, but continuous noninvasive methods for CBF monitoring are lacking. Diffuse correlation spectroscopy (DCS) is a noninvasive diffuse optical modality that measures a CBF index (CBFi) in the cortex microvasculature by monitoring the rapid fluctuations of near-infrared light diffusing through moving red blood cells. We tested the feasibility of monitoring CBFi with DCS in at-risk patients in the Neurosciences Intensive Care Unit. DCS data were acquired continuously for up to 20 h in six patients with aneurysmal subarachnoid hemorrhage, as permitted by clinical care. Mean arterial blood pressure was recorded synchronously, allowing us to derive autoregulation curves and to compute an autoregulation index. The autoregulation curves suggest disrupted cerebral autoregulation in most patients, with the severity of disruption and the limits of preserved autoregulation varying between subjects. Our findings suggest the potential of the DCS modality for noninvasive, long-term monitoring of cerebral perfusion, and autoregulation.
27 March 2021 in Journal of Biomedical Optics
In the healthy brain, and under normal intracranial pressure (ICP), cerebral autoregulation ensures that adequate constant cerebral blood flow (CBF) is maintained over a wide range of arterial blood pressures (ABP).1,2 However, in patients suffering from conditions as shock, stroke, cerebral edema, or traumatic brain injury, their cerebral autoregulation can be impaired such that changes in ABP may lead to cerebral hyperperfusion, hypoperfusion, and ischemia.3 If CBF and ICP abnormalities are discovered promptly, therapeutic interventions such as administration of vasoactive agents, osmolar agents, or changes in posture or ventilation can be successfully applied.4 – 6 Because of the possibility of disrupted autoregulation, blood pressure monitoring alone only marginally helps to assess the impacts of systemic vascular changes to brain perfusion in these patients.
21 September 2017 in Neurophotonics
This paper presents a multidistance and multiwavelength diffuse correlation spectroscopy (DCS) approach and its implementation to simultaneously measure the optical proprieties of deep tissue as well as the blood flow. The system consists of three long coherence length lasers at different wavelengths in the near-infrared, eight single-photon detectors, and a correlator board. With this approach, we collect both light intensity and DCS data at multiple distances and multiple wavelengths, which provide unique information to fit for all the parameters of interest: scattering, blood flow, and hemoglobin concentration. We present the characterization of the system and its validation with phantom measurements.
1 May 2015 in Journal of Biomedical Optics
Traditionally, diffuse correlation spectroscopy (DCS) measures microvascular blood flow by fitting a physical model to the measurement of the intensity autocorrelation function from a single source-detector pair. This analysis relies on the accurate knowledge of the optical properties, absorption, and reduced scattering coefficients of the medium. Therefore, DCS is often deployed together with diffuse optical spectroscopy. We present an algorithm that employs multidistance DCS (MD-DCS) for simultaneous measurement of blood flow index, as well as an estimate of the optical properties of the tissue. The algorithm has been validated through noise-free and noise-added simulated data and phantom measurements. A longitudinal in vivo measurement of a mouse tumor is also shown. MD-DCS is introduced as a stand-alone system for small source-detector separations () for noninvasive measurement of microvascular blood flow.
20 February 2020 in Neurophotonics
<!-- *** Custom HTML *** --> Corrected disclosures for the article “Prolonged monitoring of cerebral blood flow and autoregulation with diffuse correlation spectroscopy in neurocritical care patients.” This article [Neurophotonics 5, 045005 (2018) doi: 10.1117/1.NPh.5.4.045005] was originally published online on 13 November 2018 with an error in the Disclosures section, where information regarding potential conflicts of interest was reported incompletely. Original: The authors hold patents on the DCS technology. MAF has a financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants. MAF’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Corrected: MAF and DAB have financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants, and in Dynometrics, Inc., a company that makes devices that use NIRS technology for athletes to evaluate muscle performance. MAF and DAB interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. This article was corrected online on 11 February 2020.